Leo Pharma shows the industry how to earn money efficiently  

Leo Pharma posts record figures for 2002, with a pre-tax profit of DKK 1.8 billion on a turnover of DKK 4.4 billion

Danish pharmaceutical company Leo Pharma has posted a record set of figures for 2002, with a pre-tax profit figure of close on DKK 1.8 billion (USD 270 million) from a turnover of DKK 4.4 billion (USD 660 million) – putting the 100% foundation-owned concern second only worldwide to Pfizer on ability to generate profit from the sales of drugs. During 2002 Leo Group's equity grew to DKK 8.4 billion (USD 1.26 billion) with an equity ratio of 84% and an operating margin of 32%.


Leo Pharma has entered a new collaboration agreement with Galen Holdings Plc in relation to marketing its psoriasis drugs Daivonex and Daivobet in the US. Another focus area for 2003 is Leo Pharma's HL-10 project - potentially the world's first drug to treat ALI (acute lung injury) and ARDS (acute respiratory distress syndrome) - both regarding the results from the ongoing clinical trials, and Leo Pharma's new plant in Esbjerg on the west Jutland coast.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×